2022
CEO Steven Lydeamore presents at The Capital Network's Emerging ASX Gems investment conference
4 November 2022
Immuron (ASX:IMC) CEO Steven Lydeamore presents at The Capital Network's Emerging ASX Gems investment conference on Friday 4 November 2022.
New investor guide profiles biotech companies to watch
27 September 2022
Immuron (IMC) listed as a company to watch in the recent Stockhead investor guide.
Immuron (ASX:IMC) shifts focus to therapeutic drug candidate
19 August 2022
Immuron (IMC) has deprioritised SARS-COV-2 research to focus on the clinical development of its therapeutic drug candidates.
Immuron (ASX:IMC) tables 494pc increase in North American FY22 Travelan sales
11 July 2022
Biopharmaceutical company Immuron (IMC) has seen a 494 per cent increase in North American Travelan sales for FY22.
